Cargando…

Safety of gadoxetate disodium: results from six clinical phase IV studies in 8194 patients

BACKGROUND: Safety data on routine clinical use of gadoxetate disodium for liver magnetic resonance imaging (MRI) is not reported yet. PURPOSE: To assess the safety profile of gadoxetate disodium for liver MRI in the routine clinical setting. MATERIAL AND METHODS: Six multicenter studies were perfor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Endrikat, Jan, Kim, So Yeon, Sakaguchi, Toshiaki, Dohanish, Susan, Breuer, Josy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2015
Materias:	Contrast Media
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070494/ https://www.ncbi.nlm.nih.gov/pubmed/26048848 http://dx.doi.org/10.1177/0284185115588126

Ejemplares similares

Safety profile of gadoxetate disodium in elderly patients (≥65 years)
por: Endrikat, Jan, et al.
Publicado: (2017)

Respiratory anomalies associated with gadoxetate disodium and gadoterate meglumine: compressed sensing MRI revealing physiologic phenomena during the entire injection cycle
por: Glessgen, Carl Guillaume, et al.
Publicado: (2021)

Reduction of respiratory motion artifacts in gadoxetate-enhanced MR with a deep learning–based filter using convolutional neural network
por: Kromrey, M.-L., et al.
Publicado: (2020)

Safety of Gadobutrol: Results From 42 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million Applications
por: Endrikat, Jan, et al.
Publicado: (2016)

Long-term safety of withholding standard prophylaxis in patients with moderate chronic kidney disease
por: Nijssen, E. C., et al.
Publicado: (2022)

Intravenous contrast medium extravasation: systematic review and updated ESUR Contrast Media Safety Committee Guidelines
por: Roditi, Giles, et al.
Publicado: (2022)

Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)
por: Deray, Gilbert, et al.
Publicado: (2012)

The pharmacokinetic profile, tolerability and safety of the iodinated, non-ionic, dimeric contrast medium Iosimenol 340 injection in healthy human subjects
por: Meurer, Karoline, et al.
Publicado: (2015)

Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines
por: Stacul, Fulvio, et al.
Publicado: (2017)

Intra-arterial and intravenous applications of Iosimenol 340 injection, a new non-ionic, dimeric, iso-osmolar radiographic contrast medium: phase 2 experience
por: Meurer, Karoline, et al.
Publicado: (2015)

Post-contrast acute kidney injury – Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines
por: van der Molen, Aart J., et al.
Publicado: (2018)

Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines
por: van der Molen, Aart J., et al.
Publicado: (2018)

The fate of Gd and chelate following intravenous injection of gadodiamide in rats
por: Kindberg, Grete Mørk, et al.
Publicado: (2010)

MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine
por: Brismar, Torkel B., et al.
Publicado: (2011)

MR liver imaging with Gd-EOB-DTPA: a delay time of 10 minutes is sufficient for lesion characterisation
por: van Kessel, C. S., et al.
Publicado: (2012)

Biphasic contrast medium injection in cardiac CT: moderate versus high concentration contrast material at identical iodine flux and iodine dose
por: Rutten, Annemarieke, et al.
Publicado: (2010)

No increase in Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin excretion following intravenous contrast enhanced-CT
por: Kooiman, Judith, et al.
Publicado: (2015)

ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents
por: Neri, E., et al.
Publicado: (2015)

What Evidence Is There That Gadobutrol Causes Increasing Signal Intensity within the Dentate Nucleus and Globus Pallidus on Unenhanced T1W MRI in Patients with RRMS?
por: Agris, Jacob, et al.
Publicado: (2015)

Contrast agent and radiation dose reduction in abdominal CT by a combination of low tube voltage and advanced image reconstruction algorithms
por: Buls, Nico, et al.
Publicado: (2014)

Comparative assessment of image quality for coronary CT angiography with iobitridol and two contrast agents with higher iodine concentrations: iopromide and iomeprol. A multicentre randomized double-blind trial
por: Achenbach, Stephan, et al.
Publicado: (2016)

Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals
por: Young, Laura K., et al.
Publicado: (2018)

Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue
por: Jost, Gregor, et al.
Publicado: (2016)

Feasibility and accuracy of dual-layer spectral detector computed tomography for quantification of gadolinium: a phantom study
por: van Hamersvelt, Robbert W., et al.
Publicado: (2017)

Impact on clinical practice of updated guidelines on iodinated contrast material: CINART
por: Nijssen, E. C., et al.
Publicado: (2020)

USPIO-enhanced MRI of pelvic lymph nodes at 7-T: preliminary experience
por: Philips, Bart W. J., et al.
Publicado: (2019)

Post-contrast acute kidney injury in a hospitalized population: short-, mid-, and long-term outcome and risk factors for adverse events
por: Cheng, Wei, et al.
Publicado: (2020)

Minimal risk of contrast-induced kidney injury in a randomly selected cohort with mildly reduced GFR
por: Carlqvist, Jeanette, et al.
Publicado: (2020)

Influence of aging and gadolinium exposure on T1, T2, and T2*-relaxation in healthy women with an increased risk of breast cancer with and without prior exposure to gadoterate meglumine at 3.0-T brain MR imaging
por: Krug, Kathrin Barbara, et al.
Publicado: (2021)

Prospective multicenter assessment of patient preferences for properties of gadolinium-based contrast media and their potential socioeconomic impact in a screening breast MRI setting
por: Woolen, Sean A., et al.
Publicado: (2021)

Machine learning-based prediction of insufficient contrast enhancement in coronary computed tomography angiography
por: Lopes, R. R., et al.
Publicado: (2022)

A systematic review of the incidence of hypersensitivity reactions and post-contrast acute kidney injury after ioversol: part 2—intra-arterial administration
por: van der Molen, Aart J., et al.
Publicado: (2022)

3D-Arterial analysis software and CEUS in the assessment of severity and vulnerability of carotid atherosclerotic plaque: a comparison with CTA and histopathology
por: Fresilli, Daniele, et al.
Publicado: (2022)

Anterior chamber enhancement predicts optic nerve infiltration in retinoblastoma
por: Deike-Hofmann, Katerina, et al.
Publicado: (2022)

Risk of acute kidney injury after contrast-enhanced computerized tomography: a systematic review and meta-analysis of 21 propensity score–matched cohort studies
por: Obed, Mikal, et al.
Publicado: (2022)

Safety of gadobutrol: results of a non-interventional study of 3710 patients, including 404 children
por: Glutig, Katja, et al.
Publicado: (2018)

Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver
por: Huh, Jimi, et al.
Publicado: (2015)

Diagnostic Efficacy and Safety of Gadoxetate Disodium vs Gadobenate Dimeglumine in Patients With Known or Suspected Focal Liver Lesions: Results of a Clinical Phase III Study
por: Zech, Christoph J, et al.
Publicado: (2019)

Does gadoxetate disodium affect MRE measurements in the delayed hepatobiliary phase?
por: Plaikner, M., et al.
Publicado: (2018)

Safety and Efficacy of Gadoxetate Disodium–Enhanced Liver MRI in Pediatric Patients Aged >2 Months to <18 Years—Results of a Retrospective, Multicenter Study
por: Geller, James, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_c10f3pbbdk6erm93241m525u87